Le Lézard
Classified in: Health
Subject: PDT

Papa & Barkley to add THCa Tincture to its Releaftm Product Line


EUREKA, Calif., Nov. 17, 2017 /PRNewswire-iReach/ -- Papa & Barkley, a best-in-class manufacturer of effective cannabis-derived pain and wellness products, today announced the release of its 1:1 THCa:CBD tincture, created to give users the same healing properties as products made with THC, but with little or no psychoactivity. Papa & Barkley's innovative formulation not only includes THCa but is balanced with equal ratios of CBD to make a powerful wellness tincture that leverages the best of both cannabinoids. THCa helps with acute aches and pains, while CBD provides strong relief for inflammation and overall well-being, making the 1:1 THCa:CBD tincture unlike anything currently on the market.

"The new THCa:CBD tincture reflects our core mission - to improve the quality of people's lives by unlocking the power of the Plant," said Papa & Barkley CEO and Co-Founder, Adam Grossman. "THCa is the lesser-known cannabinoid found in raw cannabis; it has not been widely available in products because it is challenging to produce. We know that some consumers are nervous about psychoactivity. Our new tincture responds to these consumers' needs and keeps the entourage effect of CBD and THC, but with little or no psychoactivity."

Papa & Barkley creates highly effective, whole-plant products with absolutely no chemicals or solvents. The new THCa:CBD tincture is one of many items in the Company's popular "Releaf" line of wellness products. Tinctures were the most common way for patients to consume cannabis in the 1930's.  At this time, tinctures were available over the counter at drugstores. Cannabis tinctures remain popular today because they allow for precise and flexible dosing. Tinctures can be taken orally, sublingually, and even topically, making it one of the most versatile cannabis delivery methods. The Company's other tinctures are available in a 3:1 THC:CBD and 1:30 THC:CBD ratios.   

Many of Papa & Barkley's products are non-psychoactive, including its award-winning pain Releaf Balmtm. The Company offers a wide range of products and delivery methods to broaden cannabis accessibility for consumers. In its continuing efforts to introduce consumers to the benefits and multiple uses of the Plant, Papa & Barkley has made its educational handbook, PlantMade, available to help shed light on these cannabinoids and tinctures. See here: https://papaandbarkley.com/plantmade/

About the THCa:CBD Tincture

Papa & Barkley's power-packed THCa:CBD tincture is available in 15 and 30ml bottles and contains over 900mg of total cannabinoids in the 30ml bottle. It is 100% solvent-free, whole plant infused, and results in limited to no psychoactivity. While CBD provides strong relief for inflammation and overall well-being, THCa helps with acute aches and pains. Recent studies suggest THCa, which only converts into THC when heated, has the same healing properties as THC, with the added benefit of mental clarity. Papa & Barkley believes its THCa tincture, will provide and effective form of pain relief for elderly patients, weekend warriors, and others who suffer from chronic or triggered pain. Papa & Barkley tinctures can be applied sublingually (under the tongue), put into any food/beverage or even applied topically. One dose has approximately 3.7 mg THCa / 1.0 mg THC / 3.7mg CBD. Onset usually begins within 15 minutes to two hours. It can be purchased at Medmen stores in Southern California, with more stores coming soon.

 About the PlantMade Handbook:

PlantMade is an educational tool meant to inform readers of all aspects of the cannabis plant and its benefits. It is a Cannabis 101 primer, and covers the history of cannabis as a healing plant, as well as various delivery methods, and the science behind cannabinoids (such as  THCa, CBD, and THC). The guide is an example of the Company's commitment to education and tackling some of the myths around cannabis. The guide is available online here: https://papaandbarkley.com/plantmade/

About Papa & Barkley:

Papa & Barkleytm is a premium wellness brand that creates highly effective, natural products that unlock the healing power of the cannabis plant. We improve people's lives through the creation of 100% natural pain and wellness products that leverage sun-grown cannabis flowers. All of our products are produced in our licensed, state-of-the-art manufacturing facility, located in Humboldt County, California.

Founded by caring for the ones we love, we are a team of scientists, caregivers and advocates who are committed to producing safe and reliable products from the whole plant. Our products are 100% solvent free and are offered in ratios of THC and CBD for a variety of conditions. To learn more about us please visit http://www.papaandbarkley.com/.

Connect with Papa & Barkley:

Website: http://www.papaandbarkley.com

Twitter:  https://twitter.com/papaandbarkley

Facebook: https://www.facebook.com/papaandbarkley/

Instagram: https://www.instagram.com/papaandbarkley/

Media Contact: Nicole Rodrigues, NRPR Group for Papa & Barkley, (650) 815-5069, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE NRPR Group for Papa & Barkley


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: